International
The Morning Science

What science found today

‹
 

Business

FDA Rejects Promising Cancer Drug Developed in China

MedPage Today ·

FDA Rejects Promising Cancer Drug Developed in China

The Brief

  • The FDA declined to approve an investigational PD-1/VEGF bispecific antibody for an indication in non-small cell lung cancer (NSCLC), according to drugmaker Summit Therapeutics.
  • The drug was developed in China and is described by MedPage Today as closely watched.
  • The source says the drug could soon advance, but the available text does not give details on next steps.

Why it matters

Regulatory decisions determine which experimental cancer therapies reach patients, and this rejection of a closely watched bispecific antibody shows how such candidates face scrutiny when they are developed abroad.

Who’s affected

  • patients with non-small cell lung cancer
  • oncologists and clinical researchers
  • drug developers following FDA decisions

(MedPage Today) -- The FDA declined to approve a closely watched drug developed in China for an indication in non-small cell lung cancer (NSCLC), drugmaker Summit Therapeutics announced, though the investigational bispecific antibody could soon...

Timeline

  1. Summit Therapeutics announced that the FDA declined to approve the drug for NSCLC

  2. MedPageToday.com - medical news for physicians

    FDA Rejects Promising Cancer Drug Developed in China

How do you feel about this?

0 Comments

    FDA Rejects Promising Cancer Drug Developed in China – The Morning Science